Oral 24-week probiotics supplementation did not decrease cardiovascular risk markers in patients with biopsy proven NASH: A double-blind placebo-controlled randomized study

Oral 24-week probiotics supplementation did not decrease cardiovascular risk markers in patients with biopsy proven NASH: A double-blind placebo-controlled randomized study

Introduction and Objectives: Cardiovascular disease (CVD) is the major cause of death in non-alcoholic fatty liver disease (NAFLD), a clinical condition without any approved pharmacological therapy. Probiotics are often indicated for the disease, but their results are controversial in part due to th...

Full description

Bibliographic Details
Main Authors: Samantha Thifani Alrutz Barcelos, Amanda Souza Silva-Sperb, Helena Abadie Moraes, Larisse Longo, Bruna Concheski de Moura, Matheus Truccolo Michalczuk, Carolina Uribe-Cruz, Carlos Thadeu Schmidt Cerski, Themis Reverbel da Silveira, Valesca Dall'Alba, Mário Reis Álvares-da-Silva
Format: Article
Language:English
Published: Elsevier 2023-01-01
Series:Annals of Hepatology
Subjects:
non-alcoholic fatty liver disease
probiotics
microRNAs
cardiovascular risk
clinical trial
Online Access:http://www.sciencedirect.com/science/article/pii/S1665268122001119

Internet

http://www.sciencedirect.com/science/article/pii/S1665268122001119

Similar Items